NW Recovery Centers Logo
Alerts

The First Nitazene Lab Found in the U.S. Was a Baton Rouge House

DEA and East Baton Rouge deputies dismantled the first known domestic nitazene laboratory in the country. What etonitazene means for overdose response now.

8 min readBy Dr. Rachel Bennett
Quiet editorial illustration of laboratory glassware and a sealed flask on a plain workbench in warm morning light

On November 20, the DEA's New Orleans Field Division and the East Baton Rouge Sheriff's Office announced what their investigators had found eight days earlier inside a house on Cottage Hill Drive: a working chemical plant set up to make etonitazene.

The DEA describes it as the first known large-scale nitazene synthesis laboratory the agency has dismantled in the United States. The details in the release are unusually concrete — a 100-liter reactor system, temperature-control equipment, an industrial evaporator, about $250,000 in professional-grade hardware, and roughly 58 liters of liquid standing in the main reactor vessel when agents served three search warrants on November 12. Chemists from the DEA's South Central Laboratory in Dallas travelled to the scene; on November 18 the results came back confirming etonitazene. One 34-year-old Baton Rouge man now faces an added charge of possession with intent to distribute Schedule I narcotics, alongside earlier charges that include operating a fentanyl clandestine laboratory. He is being held without bond.

The court case will run its course, and nothing below depends on its outcome. The reason to look past the arrest is the word "synthesis," and the fact that it happened here.

A Reactor Is Not a Pill Press

Nearly all the nitazene that has reached American users so far arrived as imported powder or as finished counterfeit tablets. Somebody overseas made the chemical; somebody here divided it, pressed it, or stirred it into another drug. That is a repackaging operation, and its risk is measured in how evenly the powder was mixed.

A synthesis laboratory is a different object. It makes the drug from precursors. A 2025 review in Molecules lists "ease of synthesis, low production costs, and evasion of regulatory controls" among the reasons nitazenes keep reappearing on illicit markets — the chemistry is not exotic, and the equipment in Baton Rouge is the equipment of a small industrial process, not a kitchen experiment. Fifty-eight liters in one vessel is not a batch of pills. It is bulk solution at whatever concentration the operator chose, and the concentration is the operator's decision, not a pharmacist's.

The DEA release does not say how much finished product the site produced or where it went. What it does say is where the etonitazene has been showing up: more than 80% of all etonitazene exhibits the DEA seized nationwide this year originated in Louisiana, and the Louisiana State Police Crime Laboratory reports a recent uptick in nitazene-positive seizures. Those two facts sit in the same paragraph of the same document, and together they describe a state that is currently the country's etonitazene center of gravity.

What Etonitazene Does to a Body

Etonitazene was synthesized in the late 1950s at CIBA and studied as an analgesic. It was never developed into a medicine; researchers abandoned the class because the gap between a dose that relieved pain and a dose that stopped breathing was too narrow to work with, as reviews in ACS Chemical Neuroscience and Molecules both describe.

The potency estimates in the literature are why that gap matters. A 2025 review summarizes the published figures as roughly 1,000 times the potency of morphine and up to 10 to 20 times the potency of fentanyl, while noting that estimates vary widely between analogues. The same review is blunt about the mechanism of death: severe and prolonged respiratory depression. Breathing slows, stops, and stays stopped longer than it does with fentanyl.

Two practical consequences follow. The first is that a dose is not a reliable unit anymore. In a powder with unknown concentration, the difference between a usable amount and a fatal one is a few milligrams nobody can see. The second is that these compounds are frequently missed on routine hospital toxicology, a limitation flagged in a 2026 review in Current Pain and Headache Reports — which means a patient can look "opioid-negative" on a standard screen and still be dying of an opioid.

Naloxone Still Works. The Dose and the Clock Are Different.

Naloxone reverses opioid overdose by displacing the drug from the mu-opioid receptor, and it works against nitazenes. The DEA's own wording is that "standard emergency interventions may fall short and multiple doses of naloxone may be required."

The published clinical record supports that. A 2025 scoping review in the Journal of Medical Toxicology found only 19 nitazene overdose patients in the peer-reviewed literature between 2018 and 2024 — a small evidence base, and the authors say so. Among them, the median total naloxone dose was 3.06 mg for etonitazene, 6.00 mg for metonitazene, 3.00 mg for isotonitazene and 1 mg for protonitazene. Mean hospital length of stay for the etonitazene cases was about 122 hours.

That last number is the one families underestimate. Because these drugs can outlast a dose of naloxone, a person who wakes up after one spray can sink back into respiratory depression once it wears off. The working rule is: give naloxone, call 911, start rescue breaths, and stay with the person. If breathing slows again, give another dose. Leaving someone alone after a successful reversal is the specific mistake this pharmacology punishes.

What a Test Strip Can and Cannot Tell You

Fentanyl test strips answer a question about fentanyl. When nitazenes began appearing in the supply, a separate lateral-flow strip had to be developed for them; the BTNX nitazene strip reached the market in the first quarter of 2024. Independent laboratory evaluations since then describe a useful but imperfect tool.

A 2024 evaluation in the Harm Reduction Journal found limits of detection for isotonitazene of 2,000 to 3,000 ng/mL depending on manufacturing lot, with 24 of 33 tested nitazene analogues cross-reacting at concentrations at or below 9,000 ng/mL — and noted that compounds missing a specific nitro group on the molecule may read negative. A 2025 evaluation tested 36 analogues and detected 28, or 78%, with detection limits from 250 ng/mL to 100 micrograms per milliliter; it also found eight compounds that produced false negatives, and false positives when seized heroin contained caffeine above 300 micrograms per milliliter. A 2025 systematic review in Cureus concludes these strips are a preliminary screening tool and "should not be interpreted as confirmatory."

The practical translation is narrow. A positive nitazene result tells you the sample is dangerous and that naloxone needs to be within arm's reach. A negative result tells you the strip did not detect the compounds it was built to detect — not that the sample is safe. If you are going to use anyway, that distinction should change how much you use and who is in the room, not whether you carry naloxone. Our guide to fentanyl test strips and drug checking covers the mechanics.

If Someone You Know Uses

  • Treat any powder or pressed pill of unknown origin as possibly containing a nitazene or fentanyl. Counterfeit pills made to look like oxycodone or Xanax remain the most common route of unintentional exposure.
  • Do not use alone. If a person stops breathing with no one in the room, the outcome is decided by minutes.
  • Start with a fraction of what would normally be used, and wait. Potency varies bag to bag, and there is no way to eyeball it.
  • Keep naloxone where the person actually is, not in a drawer at a relative's house, and make sure a second person knows how to use it.
  • If an overdose happens: naloxone, 911, rescue breaths, stay. Repeat naloxone if breathing slows again.

Getting naloxone at a pharmacy explains how to obtain it, and our earlier alert on nitazenes in the Northshore parishes describes what the same field division found in the supply three months ago.

Where to Get Help

In Louisiana, the Department of Health publishes a directory of opioid treatment providers and a statewide naloxone standing order that lets pharmacies dispense naloxone without an individual prescription — both are linked from the department's opioid response page.

  • SAMHSA National Helpline: 1-800-662-HELP (4357). Free, confidential, 24/7.
  • 988 — the Suicide & Crisis Lifeline — also takes substance use crises and can connect callers to local services.
  • Louisiana Department of Health, Find Opioid Treatment: a searchable directory of office-based and clinic providers.

Medication for opioid use disorder — buprenorphine, methadone, or naltrexone — remains the intervention with the strongest evidence behind it, and it is what a person who has just survived a nitazene overdose most needs access to. Wanting treatment and being ready for residential care are different things; a phone call is a legitimate first step either way.

A dismantled laboratory does not mean etonitazene is gone from Louisiana. It means the state has now seen the version of this problem where the chemical is made locally — and the response that saves lives is unchanged: naloxone nearby, no one using alone, and a plan that does not depend on knowing what is in the bag.

Sources